NEJM/X
Oct 1, 2025, 15:39
Boosting Stroke Thrombolysis․ Tirofiban Shows Promise in ASSET-IT Trial
The New England Journal of Medicine (NEJM), has shared a post on X:
“ASSET-IT phase 3 trial. Guidelines recommend intravenous thrombolysis within 4.5 hours after onset of acute ischemic stroke, but vascular reocclusion may occur.
Adjunct treatment with tirofiban might improve outcomes. Research findings are summarized in a new Quick Take video.”
Read more here.
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke